Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Unity Biotechnology, Inc.
This is a blinded, multi-center study to provide approximately 1 additional year of follow-up for patients with knee OA who participated in a randomized placebo-controlled study of IA UBX0101. No intervention is planned and patients will have 4 scheduled visits to collect follow-up assessments. The primary objective is to evaluate long-term safety and tolerability of IA administration of UBX0101 in patients with painful knee OA.
Age
40–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with knee OA who have completed a randomized placebo-controlled study of UBX0101.
Patients who are willing and able to consent to having blinded, long-term follow-up; consent via legally authorized representative is not accepted.
You may not be if
Patients with any condition that, in the opinion of the Investigator, would likely interfere with adhering to the study schedule of visits for 12 months.
Patients who are scheduled to undergo knee arthroplasty on either knee during the study.
Patients who anticipate arthroscopic surgery on either knee at any time during the study.
Patients who plan to receive treatment with an anti-nerve growth factor agent during the study.
Patients who plan to participate in another investigational study (including interventional studies of investigational drugs and investigational treatments \[e.g., braces, stem cells, and procedures\]) during the study.
Clareo Health | Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo
